the performance within our genetic screening business was driven by continued expansion of prenatal screening platforms , with broad-based growth experienced across all major geographies , particularly in china with continued expansion of our newborn screening business through our acquisition of sym-bio lifescience co. , ltd. ( sym-bio ) in fiscal year 2009. in the research market , demand for our reagents and 32 instrumentation was encouraging in the academic sector . we saw strong demand for our high-end opera ® cellular imaging systems , enspire plate readers and proprietary alpha detection reagents , which are all specifically developed to address the growing needs of the academic sector . we are refocusing resources to meet our pharmaceutical customer 's evolving needs . as these customers shift their spending on downstream technologies in pre-clinical research , we are well positioned with our in-vivo imaging offering , available through our newly acquired visen business . as the rising cost of healthcare continues to be one of the critical issues facing our customers , we anticipate that even with continued pressure on lab budgets and credit availability , the benefits of providing earlier detection of disease , which can result in savings of long-term health care costs as well as creating better outcomes for patients , are increasingly valued and we expect to see continued growth in these markets . in our environmental health segment , our laboratory services business enables our customers to drive efficiencies , increase production time and reduce maintenance costs , all of which continue to be critical for our customers . during fiscal year 2010 , we continued to grow by adding new customers to our onesource ® multivendor service offering , which we expanded in markets beyond our traditional customer base and services . sales of environmental , food and consumer safety and testing products grew in fiscal year 2010 due to the continued global need for robust contaminant identification solutions , particularly for trace metals analysis in water . this trend drove the demand for our inorganic analysis solutions such as our optima 7000 and our recently launched nexion ® mass spectrometer . we also continued to experience strong demand for quality and safety assurance testing equipment in food and pharmaceuticals throughout the global supply chain . in addition , we continued to see signs of recovery in our traditional chemical markets with the reduction of constraints on capital purchases to rebuild capacity as a result of the cyclical recovery and increased demand after an extended period of delayed capital investments . we believe that the need for increased inspection , testing and tracking of contaminants will continue to drive increased demand for our products . our consolidated gross margins decreased approximately 60 basis points in fiscal year 2010 as compared to fiscal year 2009 due to changes in product mix , with growth in sales of lower gross margin product offerings , partially offset by productivity improvements and cost containment initiatives . our consolidated operating margin improved approximately 120 basis points in fiscal year 2010 as compared to fiscal year 2009 , primarily the result of increased sales volume and cost containment initiatives , partially offset by restructuring activities , increased pension expenses , initial costs on key growth initiatives and the early stage dilution from our recent acquisitions , specifically signature genomic and visen . we believe we are well positioned to continue to take advantage of the improved spending trends in our end markets and to promote our efficiencies in markets where current conditions may increase demand for certain services . overall , we believe that our strategic focus on human health and environmental health coupled with our breadth of end markets , deep portfolio of technologies and applications , leading market positions , global scale and financial strength will provide us with a strong foundation for continued growth . consolidated results of continuing operations sales 2010 compared to 2009. sales for fiscal year 2010 were $ 1,704.3 million , as compared to $ 1,550.8 million for fiscal year 2009 , an increase of $ 153.6 million , or 10 % , which includes an approximate 2 % increase in sales attributable to acquisitions and no net impact from changes in foreign exchange rates . the analysis in the remainder of this paragraph compares segment sales for fiscal year 2010 as compared to fiscal year 2009 and includes the effect of foreign exchange rate fluctuations and acquisitions . the total increase in sales reflects a $ 64.7 million , or 9 % , increase in our human health segment sales , due to an increase in diagnostics market sales of $ 54.5 million and an increase in research market sales of $ 10.2 million . our environmental health segment sales increased $ 88.9 million , or 11 % , due to increases in environmental and safety and industrial markets sales of $ 47.5 million , and an increase in laboratory services market sales of $ 41.4 million . 33 2009 compared to 2008. sales for fiscal year 2009 were $ 1,550.8 million , as compared to $ 1,659.7 million for fiscal year 2008 , a decrease of $ 108.9 million , or 7 % , which includes an approximate 3 % decrease in sales attributable to unfavorable changes in foreign exchange rates and an approximate 1 % increase from acquisitions . the analysis in the remainder of this paragraph compares segment sales for fiscal year 2009 as compared to fiscal year 2008 and includes the effect of foreign exchange rate fluctuations and acquisitions . the total decrease in sales reflects a $ 37.0 million , or 5 % , decrease in our human health segment sales , due to a decrease in diagnostics market sales of $ 22.8 million and a decrease in research market sales of $ 14.2 million . story_separator_special_tag we recorded a charge of $ 2.7 million in fiscal year 2007 related to payments for this lease obligation . the buyer filed for bankruptcy protection during the third quarter of fiscal year 2008 and was delinquent in making both its lease payments and payments for certain building expenses . the buyer ceased operations in the third quarter of fiscal year 2009 and vacated the property . we recorded an additional charge of $ 0.9 million during the third quarter of fiscal year 2009 related to waste removal and restoration costs , and reduced the estimated sublease rental payments reasonably expected to be obtained for the property . we also recorded an additional charge of $ 0.1 million during the second quarter of fiscal year 2010 to further reduce the estimated sublease rental payments reasonably expected to be obtained for the property . we were required to make payments for these obligations of $ 1.7 million during fiscal year 2010 , $ 1.1 million during fiscal year 2009 , and $ 0.4 million during fiscal year 2008. the remaining balance of this accrual as of january 2 , 2011 was $ 0.5 million . interest and other ( income ) expense , net interest and other ( income ) expense , net , consisted of the following : replace_table_token_16_th 2010 compared to 2009. interest and other ( income ) expense , net for fiscal year 2010 was income of $ 8.4 million , as compared to an expense of $ 15.8 million for fiscal year 2009 , an increase of $ 24.2 million . the increase in interest and other ( income ) expense , net , in fiscal year 2010 as compared to fiscal year 2009 was primarily due to the pre-tax gain of $ 25.6 million related to the required re-measurement to fair value of our previously held equity interest in the icpms joint venture . interest expense decreased by $ 0.1 million and interest income decreased by $ 0.2 million in fiscal year 2010 as compared to fiscal year 2009 , primarily due to lower interest rates . other expenses for fiscal year 2010 as compared to fiscal year 2009 increased by $ 1.3 million , which consisted primarily of expenses related to foreign currency transactions and foreign currency translation . a more complete discussion of our liquidity is set forth below under the heading liquidity and capital resources. 2009 compared to 2008. interest and other ( income ) expense , net for fiscal year 2009 was an expense of $ 15.8 million , as compared to an expense of $ 44.0 million for fiscal year 2008 , a decrease of $ 28.3 million . the decrease in interest and other ( income ) expense , net , in fiscal year 2009 as compared to fiscal year 2008 was primarily due to the discontinuance and settlement of forward interest rate contracts with a $ 17.5 million loss that 39 was recognized into interest expense during fiscal year 2008 , as well as lower interest rates on outstanding debt balances , partially offset by the increase in the mix of our fixed rate versus variable rate debt . interest income decreased $ 3.0 million as a result of lower interest rates on lower cash balances . other expenses for fiscal year 2009 as compared to fiscal year 2008 decreased by $ 7.3 million , and consisted primarily of expenses related to foreign currency transactions and foreign currency translation . provision for income taxes 2010 compared to 2009. the fiscal year 2010 provision for income taxes on continuing operations was $ 26.1 million , as compared to a provision of $ 31.8 million for fiscal year 2009. the effective tax rate on continuing operations was 16.1 % for fiscal year 2010 as compared to 30.0 % for fiscal year 2009. the lower effective tax rate in fiscal year 2010 was primarily due to ( i ) the favorable impact related to the gain on the previously held equity interest in the icpms joint venture , and ( ii ) the favorable settlement of several income tax audits worldwide during fiscal year 2010. see note 6 to our consolidated financial statements included in this annual report on form 10-k for further discussion of these settlements . 2009 compared to 2008. the fiscal year 2009 provision for income taxes on continuing operations was $ 31.8 million , as compared to a provision of $ 12.7 million for fiscal year 2008. the effective tax rate on continuing operations was 30.0 % for fiscal year 2009 as compared to 12.3 % for fiscal year 2008. the higher effective tax rate in fiscal year 2009 was primarily due to an increase in the expected mix of profits from higher tax rate jurisdictions in fiscal year 2009 as compared to fiscal year 2008 and reflects the favorable settlement of several income tax audits worldwide in fiscal year 2008. see note 6 to our consolidated financial statements included in this annual report on form 10-k for further discussion of these settlements . discontinued operations as part of our continuing efforts to focus on higher growth opportunities , we have discontinued certain businesses . we have accounted for these businesses as discontinued operations and , accordingly , have presented the results of operations and related cash flows as discontinued operations for all periods presented . the assets and liabilities of these businesses have been presented separately , and are reflected within the assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of january 2 , 2011 and january 3 , 2010. we recorded the following pre-tax gains and losses , which have been reported as a gain ( loss ) on disposition of discontinued operations during the three fiscal years ended : replace_table_token_17_th in november 2010 , we sold our illumination and detection solutions ( ids ) business , which was included in our environmental health segment , for approximately $ 500.0 million

cash flows fiscal year 2010 operating activities . net cash provided by continuing operations was $ 167.2 million for fiscal year 2010 , as compared to net cash provided by continuing operations of $ 127.8 million for fiscal year 2009 , an increase of $ 39.4 million . the increase in cash provided by operating activities for fiscal year 2010 was a result of income from continuing operations of $ 135.9 million , depreciation and amortization of $ 89.2 million and restructuring and lease charges , net of $ 19.0 million . these amounts were partially offset by pre-tax gains of $ 28.9 million related to the required re-measurement to fair value of our previously held equity interest in the icpms joint venture and asset dispositions , and a net increase in working capital of $ 32.9 million . contributing to the net increase in working capital for fiscal year 2010 , excluding the effect of foreign exchange rate fluctuations , was an increase in inventory of $ 22.6 million and an increase in accounts receivable of $ 38.1 million , partially offset by an increase in accounts payable of $ 27.8 million . the increase in inventory overall was primarily a result of new products within our environmental health and human health segments to improve responsiveness to customer requirements . the increase in accounts receivable was a result of higher sales volume during the fourth quarter of fiscal year 2010. the increase in accounts payable was primarily a result of the timing of disbursements during the fourth quarter of fiscal year 2010. changes in accrued expenses , other assets and liabilities and other items , net , decreased cash provided by operating activities by $ 15.0 million for fiscal year 2010 , and primarily related to the timing of payments for tax , restructuring , and salary and benefits , and included the voluntarily contribution made during the third quarter of fiscal year 2010 of $ 30.0 million to our defined benefit pension plan in the united states for the 2009 plan year . investing activities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows fiscal year 2010 operating activities . net cash provided by continuing operations was $ 167.2 million for fiscal year 2010 , as compared to net cash provided by continuing operations of $ 127.8 million for fiscal year 2009 , an increase of $ 39.4 million . the increase in cash provided by operating activities for fiscal year 2010 was a result of income from continuing operations of $ 135.9 million , depreciation and amortization of $ 89.2 million and restructuring and lease charges , net of $ 19.0 million . these amounts were partially offset by pre-tax gains of $ 28.9 million related to the required re-measurement to fair value of our previously held equity interest in the icpms joint venture and asset dispositions , and a net increase in working capital of $ 32.9 million . contributing to the net increase in working capital for fiscal year 2010 , excluding the effect of foreign exchange rate fluctuations , was an increase in inventory of $ 22.6 million and an increase in accounts receivable of $ 38.1 million , partially offset by an increase in accounts payable of $ 27.8 million . the increase in inventory overall was primarily a result of new products within our environmental health and human health segments to improve responsiveness to customer requirements . the increase in accounts receivable was a result of higher sales volume during the fourth quarter of fiscal year 2010. the increase in accounts payable was primarily a result of the timing of disbursements during the fourth quarter of fiscal year 2010. changes in accrued expenses , other assets and liabilities and other items , net , decreased cash provided by operating activities by $ 15.0 million for fiscal year 2010 , and primarily related to the timing of payments for tax , restructuring , and salary and benefits , and included the voluntarily contribution made during the third quarter of fiscal year 2010 of $ 30.0 million to our defined benefit pension plan in the united states for the 2009 plan year . investing activities .
```    
 Suspicious Activity Report : the performance within our genetic screening business was driven by continued expansion of prenatal screening platforms , with broad-based growth experienced across all major geographies , particularly in china with continued expansion of our newborn screening business through our acquisition of sym-bio lifescience co. , ltd. ( sym-bio ) in fiscal year 2009. in the research market , demand for our reagents and 32 instrumentation was encouraging in the academic sector . we saw strong demand for our high-end opera ® cellular imaging systems , enspire plate readers and proprietary alpha detection reagents , which are all specifically developed to address the growing needs of the academic sector . we are refocusing resources to meet our pharmaceutical customer 's evolving needs . as these customers shift their spending on downstream technologies in pre-clinical research , we are well positioned with our in-vivo imaging offering , available through our newly acquired visen business . as the rising cost of healthcare continues to be one of the critical issues facing our customers , we anticipate that even with continued pressure on lab budgets and credit availability , the benefits of providing earlier detection of disease , which can result in savings of long-term health care costs as well as creating better outcomes for patients , are increasingly valued and we expect to see continued growth in these markets . in our environmental health segment , our laboratory services business enables our customers to drive efficiencies , increase production time and reduce maintenance costs , all of which continue to be critical for our customers . during fiscal year 2010 , we continued to grow by adding new customers to our onesource ® multivendor service offering , which we expanded in markets beyond our traditional customer base and services . sales of environmental , food and consumer safety and testing products grew in fiscal year 2010 due to the continued global need for robust contaminant identification solutions , particularly for trace metals analysis in water . this trend drove the demand for our inorganic analysis solutions such as our optima 7000 and our recently launched nexion ® mass spectrometer . we also continued to experience strong demand for quality and safety assurance testing equipment in food and pharmaceuticals throughout the global supply chain . in addition , we continued to see signs of recovery in our traditional chemical markets with the reduction of constraints on capital purchases to rebuild capacity as a result of the cyclical recovery and increased demand after an extended period of delayed capital investments . we believe that the need for increased inspection , testing and tracking of contaminants will continue to drive increased demand for our products . our consolidated gross margins decreased approximately 60 basis points in fiscal year 2010 as compared to fiscal year 2009 due to changes in product mix , with growth in sales of lower gross margin product offerings , partially offset by productivity improvements and cost containment initiatives . our consolidated operating margin improved approximately 120 basis points in fiscal year 2010 as compared to fiscal year 2009 , primarily the result of increased sales volume and cost containment initiatives , partially offset by restructuring activities , increased pension expenses , initial costs on key growth initiatives and the early stage dilution from our recent acquisitions , specifically signature genomic and visen . we believe we are well positioned to continue to take advantage of the improved spending trends in our end markets and to promote our efficiencies in markets where current conditions may increase demand for certain services . overall , we believe that our strategic focus on human health and environmental health coupled with our breadth of end markets , deep portfolio of technologies and applications , leading market positions , global scale and financial strength will provide us with a strong foundation for continued growth . consolidated results of continuing operations sales 2010 compared to 2009. sales for fiscal year 2010 were $ 1,704.3 million , as compared to $ 1,550.8 million for fiscal year 2009 , an increase of $ 153.6 million , or 10 % , which includes an approximate 2 % increase in sales attributable to acquisitions and no net impact from changes in foreign exchange rates . the analysis in the remainder of this paragraph compares segment sales for fiscal year 2010 as compared to fiscal year 2009 and includes the effect of foreign exchange rate fluctuations and acquisitions . the total increase in sales reflects a $ 64.7 million , or 9 % , increase in our human health segment sales , due to an increase in diagnostics market sales of $ 54.5 million and an increase in research market sales of $ 10.2 million . our environmental health segment sales increased $ 88.9 million , or 11 % , due to increases in environmental and safety and industrial markets sales of $ 47.5 million , and an increase in laboratory services market sales of $ 41.4 million . 33 2009 compared to 2008. sales for fiscal year 2009 were $ 1,550.8 million , as compared to $ 1,659.7 million for fiscal year 2008 , a decrease of $ 108.9 million , or 7 % , which includes an approximate 3 % decrease in sales attributable to unfavorable changes in foreign exchange rates and an approximate 1 % increase from acquisitions . the analysis in the remainder of this paragraph compares segment sales for fiscal year 2009 as compared to fiscal year 2008 and includes the effect of foreign exchange rate fluctuations and acquisitions . the total decrease in sales reflects a $ 37.0 million , or 5 % , decrease in our human health segment sales , due to a decrease in diagnostics market sales of $ 22.8 million and a decrease in research market sales of $ 14.2 million . story_separator_special_tag we recorded a charge of $ 2.7 million in fiscal year 2007 related to payments for this lease obligation . the buyer filed for bankruptcy protection during the third quarter of fiscal year 2008 and was delinquent in making both its lease payments and payments for certain building expenses . the buyer ceased operations in the third quarter of fiscal year 2009 and vacated the property . we recorded an additional charge of $ 0.9 million during the third quarter of fiscal year 2009 related to waste removal and restoration costs , and reduced the estimated sublease rental payments reasonably expected to be obtained for the property . we also recorded an additional charge of $ 0.1 million during the second quarter of fiscal year 2010 to further reduce the estimated sublease rental payments reasonably expected to be obtained for the property . we were required to make payments for these obligations of $ 1.7 million during fiscal year 2010 , $ 1.1 million during fiscal year 2009 , and $ 0.4 million during fiscal year 2008. the remaining balance of this accrual as of january 2 , 2011 was $ 0.5 million . interest and other ( income ) expense , net interest and other ( income ) expense , net , consisted of the following : replace_table_token_16_th 2010 compared to 2009. interest and other ( income ) expense , net for fiscal year 2010 was income of $ 8.4 million , as compared to an expense of $ 15.8 million for fiscal year 2009 , an increase of $ 24.2 million . the increase in interest and other ( income ) expense , net , in fiscal year 2010 as compared to fiscal year 2009 was primarily due to the pre-tax gain of $ 25.6 million related to the required re-measurement to fair value of our previously held equity interest in the icpms joint venture . interest expense decreased by $ 0.1 million and interest income decreased by $ 0.2 million in fiscal year 2010 as compared to fiscal year 2009 , primarily due to lower interest rates . other expenses for fiscal year 2010 as compared to fiscal year 2009 increased by $ 1.3 million , which consisted primarily of expenses related to foreign currency transactions and foreign currency translation . a more complete discussion of our liquidity is set forth below under the heading liquidity and capital resources. 2009 compared to 2008. interest and other ( income ) expense , net for fiscal year 2009 was an expense of $ 15.8 million , as compared to an expense of $ 44.0 million for fiscal year 2008 , a decrease of $ 28.3 million . the decrease in interest and other ( income ) expense , net , in fiscal year 2009 as compared to fiscal year 2008 was primarily due to the discontinuance and settlement of forward interest rate contracts with a $ 17.5 million loss that 39 was recognized into interest expense during fiscal year 2008 , as well as lower interest rates on outstanding debt balances , partially offset by the increase in the mix of our fixed rate versus variable rate debt . interest income decreased $ 3.0 million as a result of lower interest rates on lower cash balances . other expenses for fiscal year 2009 as compared to fiscal year 2008 decreased by $ 7.3 million , and consisted primarily of expenses related to foreign currency transactions and foreign currency translation . provision for income taxes 2010 compared to 2009. the fiscal year 2010 provision for income taxes on continuing operations was $ 26.1 million , as compared to a provision of $ 31.8 million for fiscal year 2009. the effective tax rate on continuing operations was 16.1 % for fiscal year 2010 as compared to 30.0 % for fiscal year 2009. the lower effective tax rate in fiscal year 2010 was primarily due to ( i ) the favorable impact related to the gain on the previously held equity interest in the icpms joint venture , and ( ii ) the favorable settlement of several income tax audits worldwide during fiscal year 2010. see note 6 to our consolidated financial statements included in this annual report on form 10-k for further discussion of these settlements . 2009 compared to 2008. the fiscal year 2009 provision for income taxes on continuing operations was $ 31.8 million , as compared to a provision of $ 12.7 million for fiscal year 2008. the effective tax rate on continuing operations was 30.0 % for fiscal year 2009 as compared to 12.3 % for fiscal year 2008. the higher effective tax rate in fiscal year 2009 was primarily due to an increase in the expected mix of profits from higher tax rate jurisdictions in fiscal year 2009 as compared to fiscal year 2008 and reflects the favorable settlement of several income tax audits worldwide in fiscal year 2008. see note 6 to our consolidated financial statements included in this annual report on form 10-k for further discussion of these settlements . discontinued operations as part of our continuing efforts to focus on higher growth opportunities , we have discontinued certain businesses . we have accounted for these businesses as discontinued operations and , accordingly , have presented the results of operations and related cash flows as discontinued operations for all periods presented . the assets and liabilities of these businesses have been presented separately , and are reflected within the assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of january 2 , 2011 and january 3 , 2010. we recorded the following pre-tax gains and losses , which have been reported as a gain ( loss ) on disposition of discontinued operations during the three fiscal years ended : replace_table_token_17_th in november 2010 , we sold our illumination and detection solutions ( ids ) business , which was included in our environmental health segment , for approximately $ 500.0 million

